Abramson, Vandana G.

Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer

Murthy, R. K., Loi, S., Okines, A., Paplomata, E., Hamilton, E., Hurvitz, S. A., Lin, N. U., Borges, V., Abramson, V., Anders, C., et al. (2020) · New England Journal of Medicine

HER2/EGFR in Cancer ResearchGastric Cancer Management and Outcomes

Cited by 1,326

Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer

Bardia, A., Mayer, I. A., Vahdat, L. T., Tolaney, S. M., Isakoff, S. J., Diamond, J. R., O’Shaughnessy, J., Moroose, R. L., Santin, A. D., Abramson, V. G., et al. (2019) · New England Journal of Medicine

Breast Cancer Treatment StudiesAdvanced Breast Cancer Therapies

Cited by 874

Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial

Lin, N. U., Borges, V., Anders, C., Murthy, R. K., Paplomata, E., Hamilton, E., Hurvitz, S., Loi, S., Okines, A., Abramson, V., et al. (2020) · Journal of Clinical Oncology

Brain Metastases and TreatmentHER2/EGFR in Cancer Research

Cited by 544

Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer

Flaherty, K. T., LoRusso, P. M., DeMichele, A., Abramson, V. G., Courtney, R., Randolph, S. S., Shaik, M. N., Wilner, K. D., O'Dwyer, P. J., & Schwartz, G. K. (2012) · Clinical Cancer Research

Advanced Breast Cancer TherapiesCancer-related Molecular Pathways

Cited by 366

Time course of arthralgia among women initiating aromatase inhibitor therapy and a postmenopausal comparison group in a prospective cohort

Castel, L. D., Hartmann, K. E., Mayer, I. A., Saville, B. R., Alvarez, J., Boomershine, C. S., Abramson, V. G., Chakravarthy, A. B., Friedman, D. L., & Cella, D. F. (2013) · Cancer

Breast Cancer Treatment StudiesMenopause: Health Impacts and Treatments

Cited by 43